Prognosis analysis of primary breast diffuse large B cell lymphoma
10.3760/cma.j.issn.0253-3766.2019.03.015
- VernacularTitle: 原发性乳腺弥漫大B细胞淋巴瘤的预后分析
- Author:
Yuehong ZHU
1
;
Wenjing MENG
;
Lihong HE
;
Yongsheng JIA
;
Zhongsheng TONG
Author Information
1. Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin′s Clinical Research Center for Cancer, Tianjin 300060, China
- Publication Type:Clinical Trail
- Keywords:
Lymphoma;
Primary breast diffuse large B-cell lymphoma;
Extranodal lymphoma;
Clinicopathological characteristics;
Prognosis
- From:
Chinese Journal of Oncology
2019;41(3):235-240
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics, therapy modality and prognosis of primary breast diffuse large B-cell lymphoma(PB-DLBCL).
Methods:A total of 68 patients with PB-DLBCL treated in Tianjin Medical University Cancer Institute and Hospital were enrolled between January 1, 2004 and January 31, 2017. Clinicopathological data were retrospectively analyzed. 67 patients were female and only one male. The median age was 56 years old. 46 patients had Ann Arbor clinical stageⅠ~Ⅱ disease, and the other 22 were stage Ⅲ~Ⅳ. The patients with and without B symptom were 11 and 57, respectively. Kaplan-Meier method was used for univariate analysis to calculate the 5-year overall survival (OS) rate and 5-year progress-free survival (PFS) rate, compared using the log rank test. Cox regression analysis was used for multivariate analysis.
Results:The 1, 3, 5-year OS rate were 84.0%, 78.0% and 73.0%, and 1, 3, 5-year PFS rate were 80.0%, 71.0% and 51.0%, respectively. Univariate analysis indicated that eastern cooperative oncology group (ECOG) score, Ann Arbor clinical stage, international prognostic index (IPI) score, risk stratification, B symptom, β2-microglobulin(β2-MG) level, size of the tumor and cycles of chemotherapy were prognostic factors for OS (all P<0.05), and Ann Arbor clinical stage, IPI score, risk stratification and B symptom were prognostic factors for PFS (all P<0.05). Multivariate analysis indicated that Ann Arbor clinical stage was independent prognostic factor for OS(P=0.029) and B symptom was independent prognostic factor for PFS(P=0.028).
Conclusions:Prognosis of PB-DLBCL was relatively good. Ann Arbor clinical stage and B symptom were independent prognostic factors for OS and PFS, respectively.
